Proqr Therapeutics vs X4 Pharmaceuticals
X4 Pharmaceuticals is the larger business, with $35.1m of revenue in fiscal 2025 against $18.0m for Proqr Therapeutics (2.0 times as much). X4 Pharmaceuticals grew faster (1250.5% against -12.1%). X4 Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -225.6% against -265.2%. Proqr Therapeutics carries less debt relative to equity (9.9% against 40.3%).
| Latest fiscal year | Proqr TherapeuticsPRQR, 2025 | X4 PharmaceuticalsXFOR, 2025 |
|---|---|---|
| Revenue | $18.0m | $35.1m |
| Revenue growth | -12.1% | 1250.5% |
| Net income | −$47.7m | −$79.2m |
| Operating margin | -273.1% | -247.4% |
| Net margin | -265.2% | -225.6% |
| Return on equity | -63.8% | -76.0% |
| Free cash flow | −$60.8m | −$85.6m |
| Cash | $108m | $217m |
| Total debt | $5.7m | $75.0m |
| Debt to equity | 9.9% | 40.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 45 |
| Market value | $144m | $308m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 5 buys, 0 sales | 1 buys, 5 sales |